| Bioactivity | CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes[1][2][3]. | ||||||||||||
| Invitro | CCG-1423 (10 µM; 24 h) affects invasion by cultured PC-3 cells into a Matrigel matrix and inhibits 54% mitochondrial metabolism of WST-1[1].CCG-1423 (0-100 µM; 24 h) inhibits RhoA and RhoC signaling pathways with an IC50 value of 1.5 µM for Rho-pathway selective serum response element-luciferase reporter[1].CCG-1423 (1 µM; 16 h) improves glucose uptake in both L6 cells and primary human myotubes[2].CCG-1423 (10 µM; 18-19 h) inhibits expression of Rho downstream[2].CCG-1423 (3 µM; 25 h) selectively stimulates apoptosis of RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375)[3]. Cell Invasion Assay[1] Cell Line: | ||||||||||||
| Name | CCG-1423 | ||||||||||||
| CAS | 285986-88-1 | ||||||||||||
| Formula | C18H13ClF6N2O3 | ||||||||||||
| Molar Mass | 454.75 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
CCG-1423
CAS: 285986-88-1 F: C18H13ClF6N2O3 W: 454.75
CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.